| 倪 镌,于爱军,朱 滔.子宫肉瘤患者的临床特点及其代谢综合征与预后的关系[J].肿瘤学杂志,2019,25(5):446-449. |
| 子宫肉瘤患者的临床特点及其代谢综合征与预后的关系 |
| Clinical Characteristics and Relationship with Metabolic Syndrome and Prognosis in Uterine Sarcoma |
| 投稿时间：2019-01-05 |
| DOI：10.11735/j.issn.1671-170X.2019.05.B014 |
|
 |
| 中文关键词: 子宫肉瘤 代谢综合征 预后 |
| 英文关键词:uterine sarcoma metabolic syndrome prognosis |
| 基金项目:国家自然基金（81602267） |
|
| 摘要点击次数: 1994 |
| 全文下载次数: 431 |
| 中文摘要: |
| 摘 要：［目的］ 探讨子宫肉瘤患者的临床特点及其代谢综合征与预后的关系。［方法］ 浙江省肿瘤医院2003年1月至2010年12月间收治原发子宫肉瘤患者62例，回顾性分析子宫肉瘤的各病理类型特点及预后。［结果］ 62例子宫肉瘤患者中，随访期内存活28例，死亡34例。7年总生存率为45.2%。合并MS者8例，占12.9%；非合并MS者54例，占87.1%。子宫恶性苗勒氏管混合瘤7年总生存率为29.6%，中位生存时间36.0个月。合并MS者中位生存时间与非MS者相比差异无统计学意义（χ2=0.137，P=0.712）。平滑肌肉瘤7年总生存率为28.6%（4/14），中位生存时间31个月。子宫内膜间质肉瘤7年总生存率为76.2%（16/21），低级别组中位生存时间96.7月，高级别组中位生存时间28.1月。合并MS3例，非MS18例，合并MS者中位生存时间与非MS者相比差异无统计学意义（χ2=0.273，P=0.601）。 ［结论］ 子宫恶性苗勒氏管混合瘤、平滑肌肉瘤和高级别间质肉瘤预后极差。肿瘤分期、MS与子宫肉瘤各类型预后无明确相关。 |
| 英文摘要: |
| Abstract：［Objective］ To analyze clinical characteristics and prognosis of uterine sarcoma and their relationship with metabolic syndrome. ［Methods］ Clinical data of 62 patients with uterine sarcoma admitted in Department of Gynecologic Oncology，Zhejiang Cancer Hospital from January 2003 to December 2010 were retrospectively reviewed. The pathological characteristics and prognosis of uterine sarcoma were analyzed. ［Results］ During the follow-up period，there were 28 survivors and 34 deaths in 62 patients with uterine sarcoma with an overall survival rate(OS) of 45.2%. Among them，8 cases(12.9%) were complicated with metabolic syndrome(MS). The OS in mixed malignant mullerian tumor of the uterus(n=27) was 29.6% with a median survival of 36.0 months，there was no significant difference in median survival time between MS patients(n=5) and non-MS patients(n=22)(χ2= 0.137，P=0.712). The OS in leiomyosarcoma was 28.6%(4/14) with a median survival time of 31.0 months，and there was no MS patient in this group. The OS in stromal sarcoma was 76.2%(16/21)，the median survival time of low-grade group was 96.7 months，while that of high-grade group was 28.1 months. There was no significant difference in median survival time between MS patients(n=3) and non-MS patients(n=18)(χ2=0.273，P=0.601). ［Conclusion］ The prognosis of patients with mixed malignant mullerian tumor，leiomyosarcoma and high-grade stromal sarcomas is very poor. Tumor stage，and MS may be not correlated with the prognosis of various types of uterine sarcoma. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|